Sesalin

Sesalin

SCHEMBL8993385

CC1(C)C=Cc2c(ccc3ccc(=O)oc23)O1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 4/20 0.63
KDM4E B2RXH2 8/20 0.56
ALDH1A1 P00352 6/20 0.56
TSHR P16473 2/20 0.56
MEN1 O00255 1/20 0.56
GLA P06280 1/20 0.56
ALOX15 P16050 1/20 0.56
KMT2A Q03164 1/20 0.56
HPGD P15428 5/20 0.55
CA12 O43570 4/20 0.55
CA1 P00915 4/20 0.55
CA7 P43166 4/20 0.55
CA9 Q16790 4/20 0.55
CA13 Q8N1Q1 3/20 0.55
HSD17B10 Q99714 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MAPT P10636 2/20 0.55
NPC1 O15118 1/20 0.55
TP53 P04637 1/20 0.55
POLB P06746 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sesalin SCHEMBL29402981 1.00 PDE4D (0.63) PDE4DKDM4EALDH1A1TSHRMEN1
SCHEMBL30273157 0.78 PDE4D (1.00) PDE4DKDM4EALDH1A1MEN1GLA
SCHEMBL30273160 0.78 PDE4D (1.00) PDE4DKDM4EALDH1A1MEN1GLA
SCHEMBL31238044 0.77 PDE4D (0.69) PDE4DKDM4EALDH1A1HPGDCA12
SCHEMBL24728304 0.76 PDE4D (0.48) PDE4DKDM4EALDH1A1HPGDCA12
SCHEMBL24728286 0.75 PDE4D (0.50) PDE4DALDH1A1HPGDCYP3A4PTPN1
SCHEMBL31237832 0.75 PDE4D (1.00) PDE4DKDM4EALDH1A1HPGDCA12
SCHEMBL30589491 0.75 PDE4D (1.00) PDE4DKDM4EALDH1A1TSHRMEN1
Kanzonol W SCHEMBL29378682 0.72 TYR (0.65) PDE4DPTPN1
Dipetalolactone SCHEMBL29489962 0.72 CA12 (0.61) PDE4DKDM4EALDH1A1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10906033-B2 Synthesis and application of chiral substituted polyvinylpyrrolidinones KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2021-02-02 US disclosed
US-20200306737-A1 SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES KANSAS STATE UNIVERSITY RESEARCH FOUNDATION 2020-10-01 US disclosed
WO-2017172763-A1 SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2017-10-05 WO disclosed
EP-2001463-B1 A PHARMACEUTICAL COMPOSITION USEFUL AS ACETYL CHOLINESTERASE INHIBITORS COUNCIL SCIENT IND RES (IN) 2013-07-03 EP disclosed
US-20120277297-A1 Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2012-11-01 US disclosed
US-20120277297-A1 Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2012-11-01 US disclosed
US-8188143-B2 Pharmaceutical composition useful as acetylcholinesterase inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2012-05-29 US disclosed
US-8188143-B2 Pharmaceutical composition useful as acetylcholinesterase inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2012-05-29 US disclosed
US-20080009544-A1 Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-01-10 US disclosed
US-20080009544-A1 Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-01-10 US disclosed
WO-2007107846-A1 A PHARMACEUTICAL COMPOSITION USEFUL AS ACETYL CHOLINESTERASE INHIBITORS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009544-A1 Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors ACHE, BCHE, CHRNB1 PDE4D 573/4885KDM4E 1482/4885ALDH1A1 1025/4885
US-20200306737-A1 SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES POLRMT, CNBP, DHPS PDE4D 3542/4885KDM4E 1265/4885ALDH1A1 626/4885
US-10906033-B2 Synthesis and application of chiral substituted polyvinylpyrrolidinones POLRMT, CNBP, DHPS PDE4D 3542/4885KDM4E 1265/4885ALDH1A1 626/4885
US-20120277297-A1 Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors ACHE, BCHE, CYP3A7 PDE4D 467/4885KDM4E 1461/4885ALDH1A1 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.